Elsevier

Annals of Oncology

Volume 13, Issue 3, March 2002, Pages 357-360
Annals of Oncology

Reviews
FDG-PET imaging in the management of non-small-cell lung cancer

https://doi.org/10.1093/annonc/mdf106Get rights and content
Under an Elsevier user license
open archive

Abstract

Lung cancer is currently the leading cause of cancer-related death in both men and women in most Western countries. Tumour stage is the strongest prognostic factor and the most important parameter guiding treatment decision making. Metabolic positron emission tomography imaging with fluorodeoxyglucose (FDG-PET) has consistently proved superior to conventional imaging for staging of non-small-cell lung cancer and provides information of greater prognostic significance than can be obtained using conventional approaches. FDG-PET has been approved in the USA, Germany and the UK as a basic and invaluable tool in the management of lung cancer.

Keywords

FDG-PET
non-small-cell lung cancer
outcome
staging
treatment

Cited by (0)